
Hypertension, a leading global cause of death, has increased due to rising diabetes and obesity rates. Despite current treatments, many patients fail to control blood pressure. Aprocitentan, a novel dual endothelin receptor antagonist, exemplifies emerging therapies. Addressing challenges like genetic factors, poor adherence, and therapeutic inertia, alongside innovative treatments, could significantly reduce hypertension's global impact and related cardiovascular diseases.
Like
Save
Share